Transcera Inc.
Engineered biologics and therapeutics derived from academic discoveries in the Lencer and Chinnapen labs
- Sector
- Biotech
- Headquarters
- JAMAICA PLAIN, MA
- Founded
- 2020
- Latest Form D
- $10K, Nov 2021
- Total capital
- $1.3M
- Federal grants
- $325K
- 1 award · 2023
- At sector median 1 award
- Private capital raised
- $1M
- 2 Form D · last Nov 2021
- 60 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Oral Delivery of Therapeutic Peptides for Type II Diabetes and Obesity by Harnessing Endogenous Sphingolipid Trafficking$325K
- Private capital raisedForm D · SEC · 2nd filing$10K
- Private capital raisedForm D · SEC · 1st filing$1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Phil Hunter GrayeskiDirectorNamed in SEC Form D filings
- Wayne LencerExecutive Officer, DirectorNamed in SEC Form D filings
- William Hunter GobleExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 2- PendingCompounds For Lysosomal Degradation Of Target ProteinsUSPTOApplication PCTUS2025023351
- PendingCompounds For Lysosomal Degradation Of Target ProteinsUSPTOApplication 63575520
Related companies, and why
- Foresite LabsSimilar federal contract value in Biotech · $3K in contracts
- Veloxis PharmaceuticalsSimilar federal contract value in Biotech · $83 in contracts
- Protagenic Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- GreenJay Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- LYST THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- Mongoose Bio, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .